

Laboratory Service Report

1-800-533-1710

MCR

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,JAK2B	SA00067485	47	F	SA00067485
Ordering Phys		-		DOB
CLIENT, CLIENT			06/10/1966	
Client Order #	Account Information	Account Information		Report Notes
SA00067485				
Collected	C7028846-DLMP Ro	C7028846-DLMP Rochester		
05/14/2014 00:00	SDSC 2 - Client Support			
Printed	Rochester, MN 55901			
05/15/2014 14:46				

Test Flag Results Unit Value Site*

JAK2 V617F Mutation Detection, B

Peripheral blood, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 20% of total JAK2 DNA.

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50-60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

Signing Pathologist: Melissa Tricker-Klar
Method summary - JAK2 V617F analysis: Quantitative,
allele-specific polymerase chain reaction (PCR) assay was
performed using extracted genomic DNA to evaluate for the
point mutation causing JAK2 V617F. The analytic
sensitivity of this assay has been determined at 0.01% (see
Mayo Medical Laboratories Interpretive Handbook for method
details).

Laboratory developed test. PDF Report available at:

https://test.mmlaccess.com/Reports/C7028846-GeZ3emHAx2.ashx

RECEIVED: 05/15/2014 10:15 **REPORTED:** 05/15/2014 12:36

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus	Lab Director: Franklin B. Cookerill III M.D.	
	200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.	

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,JAK2B	05/14/2014 00:00	Final
Page 1 of 1		** End of Report **

^{*} Report times for Mayo performed tests are CST/CDT



Performing Site:

Mayo Clinic Laboratories - Rochester Main Campus 200 First Street SW, Rochester MN 55905 Franklin R. Cockerill, M.D. Lab Director

Phone: 800-533-1710

http://www.mayomedicallaboratories.com

SAMPLEREPORT, JAK2B

MEDICAL RECORD # (PATIENT ID) SA00067485

 DOB
 06/10/1966
 CLIENT ID/WARD
 7028846
 ORDER #
 C215000227

 SEX
 Female
 CLIENT/NAME WARD DLMP Rochester
 CLIENT ORDER #
 SA00067485

 CLIENT MRN
 SA00067485
 CITY, ST, ZIP
 Rochester
 DATE COLLECTED 5/14/2014 12:00 AM

 REQUESTED BY CLIENT CLIENT
 MN
 55901
 DATE RECEIVED 5/15/2014 10:15 AM

DATE REPORTED 5/15/2014 12:36 PM

JAK2 V617F Mutation Detection, B

Interpretation

Peripheral blood, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 20% of total JAK2 DNA.

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50-60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

Signing Pathologist: Melissa Tricker-Klar

Method:

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.01% (see Mayo Medical Laboratories Interpretive Handbook for method details).

Disclaimer:

Laboratory developed test.

PATIENT NAME: SAMPLEREPORT, JAK2B

Site ID: C7028846 Accession Number: SA00067485

FileName: SA00067485-7WKfNO

+py219z9P11FbY4KmGITtZkzZ2gYo_tJABi9nxMlNer6Qv9MdozwDIuQyka0gYxIV6KQ_+PVZHLQKRA==.pdf
Reported Date & Time: 05/15/14 12:38
Test Name: JAK2 V617F Mutation Detection, B
Result Name: JAK2 V617F Mutation Detection, B